BACK

CD19 inhibition

CompoundSurovatamig

Area under investigation

B-ALL, B-Cell non-Hodgkin lymphoma, FL, CLL, DLBCL/LBCL, MCL

Scientific PillarT-Cell Engager

Target Overview

CD19 is a pan B-cell marker which is recognized as an immunotherapy target for multiple B cell malignancies and autoimmune diseases.1,2 CD19 targeted agents, including antibodies, ADCs and CARTs are approved for multiple B cell cancers.3

Compound Overview

Surovatamig (formerly TNB-486 and AZD0486) is a potent, bispecific T-cell engager (TCE) that binds to CD19 preferentially and engages the T cells through CD3 moiety (CD19xCD3).4 

High-affinity CD19 domain of Surovatamig binds the tumor cells, while the low-affinity CD3 binding recruits T cells resulting in target cell lysis.4

Mechanism of Action

  • Mechanism of Action

MoA image adapted from Malik-Chaudhry et al MAbs (2021).

References

1. Hammer O. MAbs. 2012;4(5):571-577. 2. Gambella M, Carlomagno S, Raiola AM, et al. Front Immunol. 2022;13:837457. 3. Viardot A, Locatelli F, Stieglmaier J, et al. Ann Hematol. 2020;99(10):2215-2229. 4. Malik-Chaudhry HK, Prabhakar K, Ugamraj HS, et al. MAbs. 2021;13(1):1890411.

Clinical trial information


Select trial for more information

Arrange By

Abbreviations

View full glossary

  • B-ALL

    B-cell acute lymphoblastic leukemia

  • BR

    bendamustine/rituximab

  • CAR-T

    chimeric antigen receptor T cell (therapy)

  • CD19

    cluster of differentiation 19

  • CD3

    cluster of differentiation 3

  • CLL

    chronic lymphocytic leukemia

  • CNS

    central nervous system

  • CR

    complete response

  • CRR

    complete response rate

  • DLBCL

    diffuse large B-cell lymphoma

  • DoCR

    duration of complete response

  • DoR

    duration of response

  • ECOG

    Eastern Cooperative Oncology Group

  • Fc

    fragment crystallizable region

  • FDG

    fluorodeoxyglucose

  • FL

    Follicular lymphoma

  • GELF

    Groupe d'Étude des Lymphomes Folliculaires

  • HGBL

    High grade B-cell lymphoma

  • ICF

    informed consent form

  • LBCL

    large b-cell lymphoma

  • MCL

    mantle cell lymphoma

  • MDS

    myelodysplastic syndrome

  • MM

    multiple myeloma

  • MOA

    mechanism of action

  • ORR

    overall or objective response rate

  • OS

    overall survival

  • PFS

    progression-free survival

  • PFS2

    time from randomization to second progression or death

  • ph3

    Phase 3

  • PK

    pharmacokinetics

  • R-CHOP

    rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

  • RCVP

    rituximab + cyclophosphamide + vincristine + prednisone

  • RP3D

    recommended phase 3 dose

  • R/R

    relapsed/refractory

  • SoC

    standard of care

  • TCE

    T-cell engager

  • TFST

    time to first subsequent therapy or death

  • WHO

    World Health Organization

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-80919 US-109129 DE-92568 Last Updated April 20263/26
©2026 AstraZeneca. All rights reserved.